BioSpace News Archive

iCAD, Inc. announced that it will release financial results for the first quarter ended March 31, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Monday, May 11.

Prevail Therapeutics Inc. announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the Bank of America Global Research Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m.

ArTara Therapeutics, Inc., a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, announced the grants of inducement non-qualified stock options to purchase an aggregate of 4,100 shares of common stock to two new employees.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced the closing of its previously announced underwritten public offering of 2.2 million shares of common stock and Series F warrants to purchase up to 2.2 million shares of common stock.

Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, announced that management will present at the 2020 Bank of America Health Care Conference on Tuesday, May 12, 2020, at 3:00pm EDT.

Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced financial results for its fiscal third-quarter 2020 and provided an update on recent business activity.

Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr for the treatment of complicated urinary tract infection and acute pyelonephritis.

Neurocrine Biosciences, Inc. will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020.

Zogenix, Inc., a global pharmaceutical company developing rare disease therapies, announced financial results for the three months ended March 31, 2020, and provided a corporate update.

Portola Pharmaceuticals, Inc.® announced that it is cancelling its webcast and conference call to discuss the Company’s financial results for the first quarter ended March 31, 2020 that was previously scheduled for Monday, May 11, 2020, at 4:30 p.m. ET.